Engulfing Line (Bearish)
|Bid||0.00 x 1100|
|Ask||0.00 x 1800|
|Day's Range||19.11 - 19.50|
|52 Week Range||14.87 - 22.47|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||40.83|
|Earnings Date||Aug 01, 2023 - Aug 07, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.40|
Subscribe to Yahoo Finance Plus to view Fair Value for EXELLearn more
SAN FRANCISCO, May 31, 2023--Farallon Capital Management, L.L.C. ("Farallon") manages funds that own approximately 7.8% of the outstanding shares of Exelixis, Inc. (NASDAQ: EXEL) ("Exelixis" or the "Company"), making it the Company’s largest active shareholder. Farallon today commented on the preliminary results of Exelixis’ 2023 Annual Meeting of Shareholders (the "Annual Meeting"), including the election to the Board of Directors (the "Board") of all three Farallon director candidates: Tom Hey
ALAMEDA, Calif., May 30, 2023--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in June:
Key Insights Significantly high institutional ownership implies Exelixis' stock price is sensitive to their trading...
Let's consider two examples: Exelixis (NASDAQ: EXEL) and Snap (NYSE: SNAP). Until that happens, biotech companies like Exelixis will be incredibly valuable. Exelixis has created an in-house culture centered around developing oncology medicines, particularly where an unmet need exists.
With that said, let's consider two biotech stocks, neither of which is a household name, that could deliver solid returns over the next five years and more: Exelixis (NASDAQ: EXEL) and Sarepta Therapeutics (NASDAQ: SRPT). Oncology is one of the most fiercely competitive therapeutic areas in the biotech industry. Exelixis, a mid-cap biotech, is just a small player in the field.
The biotech industry's biggest names tend to receive most of the attention. It may only take a few positive clinical updates, regulatory decisions, or a single successful drug to turn a biotech company's fortunes around. It grew from a $4 billion company into a $59 billion company thanks to the success of its coronavirus vaccine.
A sizable dip in the innovation-driven Nasdaq Composite is the perfect excuse for investors to pounce on some phenomenal deals.
Key Insights Exelixis' estimated fair value is US$37.88 based on 2 Stage Free Cash Flow to Equity Exelixis' US$19.35...
Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.
Thank you, Tawanda, and thank you all for joining us for the Exelixis first-quarter 2023 financial results conference call. Joining me on today's call are Mike Morrissey, our president and CEO; Chris Senner, our chief financial officer; P.J. Haley, our executive vice president of commercial; Dana Aftab, our scientific officer; and Vicki Goodman, our chief medical officer, who will review our progress for the first-quarter 2023 ending March 31st, 2023. This includes statements about possible developments regarding discovery, product development, regulatory, commercial, financial, and strategic matters.
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Exelixis (EXEL) delivered earnings and revenue surprises of -30.43% and 4.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ALAMEDA, Calif., May 09, 2023--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.
Exelixis Inc's (NASDAQ: EXEL) board member Lance Willsey announced his resignation from the Board, effective immediately. "The board supports Dr. Willsey's decision, which will end the need for Farallon to continue its proxy campaign," Exelixis said in a statement. Willsey's decision to resign was related to a "personal matter that occurred more than a decade ago," the Company said without elaborating. Exelixis also recommended that shareholders vote in favor of its remaining ten director nomine
Let us look at five biotech companies, NVAX, EBS, BLUE, EXEL and NKTR, which are gearing up for their earnings release.
SAN FRANCISCO, May 08, 2023--Funds managed by Farallon Capital Management, L.L.C. ("Farallon") own approximately 7.2% of the outstanding shares of Exelixis, Inc. (NASDAQ: EXEL) ("Exelixis" or the "Company"), making it the Company’s largest active shareholder. Farallon nominated three exceptional candidates for election to the Exelixis Board of Directors (the "Board") at the upcoming Annual Meeting of Shareholders, which will be held on May 31, 2023. Exelixis had previously agreed to support two
Biotechnology company Exelixis said on Sunday that Lance Willsey was leaving its board and that it would not contest the election of a dissident director candidate amid a proxy battle with investor Farallon Capital Management. "The board supports Dr. Willsey's decision, which will end the need for Farallon to continue its proxy campaign," Exelixis, which develops cancer therapies, said in a statement late on Sunday. Willsey's decision to resign was related to a "personal matter that occurred more than a decade ago," the company said without elaborating.
ALAMEDA, Calif., May 07, 2023--Exelixis, Inc. (Nasdaq: EXEL) (the "Company") today announced that Lance Willsey, M.D. has informed the Board of Directors of his decision to resign from the Board, effective immediately. The Board recommends shareholders vote in favor of its remaining 10 director nominees and will not contest the election of Farallon Capital Management’s ("Farallon") additional nominee, David Johnson, at the upcoming 2023 Annual Meeting of Shareholders, to be held on May 31, 2023.
ALAMEDA, Calif., May 03, 2023--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the BofA Securities 2023 Healthcare Conference on Wednesday, May 10 at 1:40 p.m. ET / 10:40 a.m. PT.
SAN FRANCISCO, May 03, 2023--Funds managed by Farallon Capital Management, L.L.C. ("Farallon") own approximately 7.2% of the outstanding shares of Exelixis, Inc. (NASDAQ: EXEL) ("Exelixis" or the "Company"), making it the Company’s largest active shareholder. Today, Farallon filed definitive proxy materials in connection with Exelixis’ 2023 Annual Meeting of Shareholders (the "Annual Meeting"), which has been scheduled for May 31, 2023. Farallon also sent a letter today to the Company’s sharehol
ALAMEDA, Calif., May 01, 2023--Exelixis, Inc. (Nasdaq: EXEL) (the "Company") today announced that it has filed its definitive proxy materials with the Securities and Exchange Commission ("SEC") in connection with its 2023 Annual Meeting of Stockholders (the "Annual Meeting"), which will be held on May 31, 2023. Shareholders of record as of April 3, 2023, will be entitled to vote at the meeting.
ALAMEDA, Calif., April 25, 2023--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.
EXEL vs. ILMN: Which Stock Is the Better Value Option?
The consensus price target hints at a 36.5% upside potential for Exelixis (EXEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Opportunistic investors would be wise to pounce on innovative growth stocks following a 33% decline in the Nasdaq Composite.